<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Meet the New Drugs: Same as the Old Drugs</title>
	<atom:link href="http://blog.pharmtech.com/2011/08/22/meet-the-new-drugs-same-as-the-old-drugs/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.pharmtech.com/2011/08/22/meet-the-new-drugs-same-as-the-old-drugs/</link>
	<description>The blog of Pharmaceutical Technology magazine</description>
	<lastBuildDate>Thu, 09 May 2013 23:30:55 -0400</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Raj Manda</title>
		<link>http://blog.pharmtech.com/2011/08/22/meet-the-new-drugs-same-as-the-old-drugs/comment-page-1/#comment-39973</link>
		<dc:creator>Raj Manda</dc:creator>
		<pubDate>Fri, 26 Aug 2011 14:16:06 +0000</pubDate>
		<guid isPermaLink="false">http://blog.pharmtech.com/?p=4577#comment-39973</guid>
		<description>It makes perfect sense! May be pharma companies will learn to think outside the box for a change and probe deeper into the enormous possibilities this findings open up for validating the already approved drugs for new indications. since the safety and dose profiles are already established, it will be a shorter and cheaper development path and save huge costs making branded drugs more affordable.</description>
		<content:encoded><![CDATA[<p>It makes perfect sense! May be pharma companies will learn to think outside the box for a change and probe deeper into the enormous possibilities this findings open up for validating the already approved drugs for new indications. since the safety and dose profiles are already established, it will be a shorter and cheaper development path and save huge costs making branded drugs more affordable.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Nancy Bloeser</title>
		<link>http://blog.pharmtech.com/2011/08/22/meet-the-new-drugs-same-as-the-old-drugs/comment-page-1/#comment-39952</link>
		<dc:creator>Nancy Bloeser</dc:creator>
		<pubDate>Thu, 25 Aug 2011 14:17:00 +0000</pubDate>
		<guid isPermaLink="false">http://blog.pharmtech.com/?p=4577#comment-39952</guid>
		<description>Eric, good article.  Finding new uses for existing medicines is indeed one example of &#039;incremental innovation,&#039; which has very high value to all stake-holders, as you point out.  While some are found via computer analyses, many are discovered by clinicians using product. 

Such incremental innovation is extremely important and should be highly praised.  

The vast majority of innovation in all fields is incremental. Most improvements and expanded uses of machinery, technology, transportation, communications, etc. are shown to be incremental.  Blockbusters in all fields are rare. Even advances in knowledge is incremental.  Medical practices are improved incrementally. 

In short, what we learn (knowledge) and how we apply it (technology) usually doesn&#039;t grow in leaps and bounds, but rather inches its way along, step by step.</description>
		<content:encoded><![CDATA[<p>Eric, good article.  Finding new uses for existing medicines is indeed one example of &#8216;incremental innovation,&#8217; which has very high value to all stake-holders, as you point out.  While some are found via computer analyses, many are discovered by clinicians using product. </p>
<p>Such incremental innovation is extremely important and should be highly praised.  </p>
<p>The vast majority of innovation in all fields is incremental. Most improvements and expanded uses of machinery, technology, transportation, communications, etc. are shown to be incremental.  Blockbusters in all fields are rare. Even advances in knowledge is incremental.  Medical practices are improved incrementally. </p>
<p>In short, what we learn (knowledge) and how we apply it (technology) usually doesn&#8217;t grow in leaps and bounds, but rather inches its way along, step by step.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
